AMGN stock forecast, quote, news & analysis

Key Takeaways

• Amgen (AMGN) shares rose roughly 10.6% over the last 30 days, climbing from a close near $421.51 in late September to about $466.01 in late October.
• Positive late-stage pipeline data, including Phase 3 results for IMDELLTRA and Tezspire, was a key driver of the rally.
• Multiple analysts raised price targets during the period, with firms including RBC Capital, TD Cowen, and Piper Sandler maintaining constructive ratings.
• Over the last quarter, the stock gained about 21%, building on a strong second-quarter earnings report and a raised full-year outlook.
• Amgen also declared a $2.52 per-share fourth-quarter dividend, reinforcing its appeal to income-focused investors.
• For more detail on Amgen's Price Targets, Earnings, and Forecast, explore the dedicated AMGN analysis pages.
• Traders can also explore automated strategies in the curated Trending AI Robots section.

Amgen (AMGN) Company Overview and Market Position

Amgen Inc. is one of the world's largest independent biotechnology companies, headquartered in Thousand Oaks, California. Founded in 1980, the company discovers, develops, manufactures, and delivers biologic and small-molecule therapies across oncology, inflammation, bone health, cardiovascular disease, rare disease, and metabolic conditions including obesity. Its portfolio includes well-known medicines such as Repatha, Prolia, XGEVA, EVENITY, Otezla, Enbrel, Tezspire, Tepezza, IMDELLTRA, and Vectibix, alongside a deep pipeline that features MariTide, an investigational GLP-1-based obesity candidate. Amgen is a component of the Dow Jones Industrial Average and the Nasdaq-100 Index, with a market capitalization near $245 billion. Investors follow the stock closely for its diversified revenue base, strong cash generation, dividend track record, and its efforts to offset patent expirations on legacy drugs with newer growth products.

Amgen (AMGN) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, AMGN advanced roughly 10.6%, moving from a closing price near $421.51 on September 30 to about $466.01 in late October. The advance was not perfectly linear; shares eased early in the month before staging a steady climb through the back half of October, ultimately breaking to new all-time highs above the prior record near $447.

The last quarter tells a broader recovery story. After finishing July near the $385 area, the stock has gained about 21% over roughly three months. The period included a sharp single-session decline in early September, followed by a sustained rebound driven by a string of clinical and analyst catalysts. The combined 30-day and quarterly moves reflect momentum that has outpaced the broader market over the same windows.

What Drove AMGN Stock Price in the Last 30 Days

Pipeline momentum was the dominant theme. Amgen presented positive Phase 3 data showing that IMDELLTRA, combined with AstraZeneca's AZN Imfinzi, reduced the risk of death by an unprecedented 58% in first-line extensive-stage small cell lung cancer. Separately, the company reported that Tezspire delivered histologic remission and symptom improvement in eosinophilic esophagitis, a potential new indication for the asthma therapy.

Analyst activity reinforced the move. RBC Capital raised its price target to $430 from $400 while maintaining an Outperform rating, and TD Cowen reiterated a Buy rating with a $452 target. Piper Sandler also issued a Buy rating, while Citi maintained a more cautious Hold. Amgen additionally declared a $2.52 per-share fourth-quarter dividend and announced a board appointment. A minor regulatory note—an FDA concern over a promotional video for Vectibix—was disclosed as an unreleased draft that Amgen said it had already corrected.

What Drove AMGN Stock Performance Over the Last Quarter

The quarterly gain was built on fundamentals. In early August, Amgen reported second-quarter revenue of about $10.05 billion, up 10% year over year, and raised its full-year 2026 revenue guidance to a midpoint of $38.8 billion while lifting its adjusted earnings outlook. Growth from newer products such as Repatha, EVENITY, IMDELLTRA, and Tezspire more than offset declines in older drugs facing biosimilar competition.

The quarter also featured a notable volatility event. In early September, a failed competitor study from NVS Novartis triggered a sharp, brief sell-off as investors reassessed Amgen's olpasiran program. Amgen recovered quickly, and positive Phase 3 data for dazodalibep in Sjögren's disease later in September helped restore momentum, pushing shares toward record territory by late October.

Trending AI Robots

Tickeron's Trending AI Robots page highlights a curated selection of automated trading strategies. Tickeron offers hundreds of AI trading bots that monitor thousands of tickers, but only the top-performing and most relevant bots are featured in this section. These bots vary widely in strategy, trading timeframe, and performance metrics, giving traders a range of approaches to evaluate rather than a single one-size-fits-all system. The page is designed to help users quickly identify strategies that are currently resonating with market conditions. Exploring the section can offer a useful starting point for those interested in data-driven, automated approaches to trading.

AMGN Stock Forecast Drivers: What Investors Should Watch Next

Investors should monitor several near-term factors. Amgen is scheduled to report third-quarter 2026 results in early November, with revenue, adjusted earnings, and any updates to full-year guidance likely to set the tone. Analysts have projected modest year-over-year growth for the quarter, and commentary on growth products and legacy-drug erosion will matter. Regulatory milestones, including the path forward for MariTide in obesity and additional label expansions for IMDELLTRA and Tezspire, remain key pipeline catalysts. Competitive dynamics in GLP-1 obesity treatments and the broader biosimilar landscape also warrant attention, as do macroeconomic pressures on healthcare spending and drug-pricing policy. As with any investment, the information here is informational and does not constitute financial advice.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations